October 12, 2009-Vaccinating boys against human papillomavirus (HPV) in addition to girls is not likely to be cost-effective, conclude a new analysis and an accompanying editorial published online October 8 in the British Medical Journal
In the United States, this use of Gardasil-i.e., vaccinating boys to protect against genital warts-was recently recommended for approval by a US Food and Drug Administration Advisory Committee, as reported
by Medscape Oncology
However, the new analysis concludes that "including boys in an HPV vaccination program is unlikely to provide good value for resources, compared with vaccinating girls only.
Free registration to read article: http://www.medscape.com/viewarticle/...ne&uac=87363SX